Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists

Czech version

Authors: Filip Gabalec; Jan Čáp; Jakub Radocha
Authors‘ workplace: IV. interní hematologická klinika LF UK a FN Hradec Králové
Published in: Vnitř Lék 2017; 63(9): 561-565
Category: Reviews

Overview

Adverse effect of dopamine agonists on the heart valves aroused much attention some time ago. Gradually, as data accumulated, the approach to the problem was rationalised and further examinations were only recommended in indicated cases. The paper reviews the current knowledge about the treatment of hyperprolactinemia with dopamine agonists and the risk of valvular disease.

Key words:
dopamine agonists – ergolines/adverse effects – heart valve diseases – hyperprolactinemia – pituitary neoplasms – prolactinoma

Sources

1. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson‘s disease. N Engl J Med 2005; 353(10): 1021–1027.

2. Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356(1): 29–38.

3. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson‘s disease. N Engl J Med 2007; 356(1): 39–46.

4. dos Santos Nunes V, El Dib R, Boguszewski CL et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 2011; 14(3): 259–265. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–010–0290-z>.

5. Gillam MP, Molitch ME, Lombardi G et al. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27(5): 485–534.

6. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014; 174(12): 1930–1933. Dostupné z DOI: <http://dx.doi.org/10.1001/jamainternmed.2014.5262>.

7. Andela CD, Scharloo M, Pereira AM et al. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 2015; 18(5): 752–776. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–015–0636–7>.

8. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9): 581–588. Erratum in N Engl J Med 1997; 337(24): 1783.

9. Pellikka PA, Tajik AJ, Khandheria BK et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87(4): 1188–1196.

10. Robiolio PA, Rigolin VH, Wilson JS et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92(4): 790–795.

11. Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102(23): 2836–2841.

12. Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005; 513(3): 225–228.

13. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356(1): 6–9.

14. Hutcheson JD, Ryzhova LM, Setola V et al. 5-HT(2B) antagonism arrests non-canonical TGF-beta1-induced valvular myofibroblast differentiation. J Mol Cell Cardiol 2012; 53(5): 707–714. Dostupné z DOI: <http://dx.doi.org/10.1016/j.yjmcc.2012.08.012>.

15. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22(6): 724–763.

16. Pivonello R, Ferone D, Lombardi G et al. Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007; 156(Suppl 1): S13-S21. Erratum in Eur J Endocrinol 2007; 157(4): 543.

17. Molitch ME. Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis? Nature reviews. Endocrinology 2011; 7(5): 254–255. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2011.33>.

18. Vroonen L, Jaffrain-Rea ML, Petrossians P et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 2012; 167(5): 651–662. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0236>. Erratum in Eur J Endocrinol 2012; 167(6): 887.

19. Hu J, Zheng X, Zhang W et al. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 2015; 18(5): 745–751. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–014–0617–2>.

20. Dekkers OM, Lagro J, Burman P et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95(1): 43–51. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2009–1238>.

21. Zanettini R, Antonini A, Gatto G et al. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther 2011; 29(6): 404–410. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1755–5922.2010.00169.x>.

22. Colao A, Galderisi M, Di Sarno A et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93(10): 3777–3784. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2007–1403>.

23. Halperin I, Aller J, Varela C et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf) 2012; 77(2): 275–280. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2012.04349.x>.

24. Elenkova A, Shabani R, Kalinov K et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 2012; 167(1): 17–25. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0121>.

25. Boguszewski CL, dos Santos CM, Sakamoto KS et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 2012; 15(1): 44–49. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–011–0339–7>.

26. Tan T, Cabrita IZ, Hensman D et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 2010; 73(3): 369–374. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2010.03827.x>.

27. Herring N, Szmigielski C, Becher H et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009; 70(1):104–108. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2008.03458.x>.

28. Vallette S, Serri K, Rivera J et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12(3): 153–157. Dostupné z DOI: <http://dx.doi.org/10.1007/s11102–008–0134–2>.

29. Devin JK, Lakhani VT, Byrd BF et al. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 2008; 14(6): 672–677.

30. Bogazzi F, Buralli S, Manetti L et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 2008; 62(12): 1864–1869. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1742–1241.2008.01779.x>.

31. Kars M, Delgado V, Holman ER et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93(9): 3348–3356. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2007–2658>.

32. Lancellotti P, Livadariu E, Markov M et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008; 159(1): 1–5. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08–0213>.

33. Wakil A, Rigby AS, Clark AL et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159(4): R11-R14. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08–0365>.

34. Lafeber M, Stades AM, Valk GD et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 2010; 162(4): 667–675. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-09–0989>.

35. Khare S, Lila AR, Patil R et al. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma. Indian J Endocrinol Metab 2017;21(1):154–159. Dostupné z DOI: <http://dx.doi.org/10.4103/2230–8210.196010>.

36. Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol 2015; 3(11): 906–913. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(14)70212–8>. Erratum in Lancet Diabetes Endocrinol 2015; 3(11): e10.

37. De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz 2013; 38(8): 868–880. Dostupné z DOI: <http://dx.doi.org/10.1007/s00059–013–3816–0>.

38. Delgado V, Biermasz NR, van Thiel SW et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf) 2012; 77(1): 99–105. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2011.04326.x>.

39. Auriemma RS, Pivonello R, Perone Y et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 2013; 169(3): 359–366. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-13–0231>.

40. Drake WM, Stiles CE, Bevan JS et al. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. J Clin Endocrinol Metab 2016; 101(11): 4189–4194.

41. Vroonen L, Lancellotti P, Garcia MT et al. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine 2017; 55(1): 239–245. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–016–1120–5>.

42. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96(5): 1327–1335. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2010–2443>.

43. Pivonello R, De Martino MC, Cappabianca P et al. The medical treatment of Cushing‘s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009; 94(1): 223–230. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008–1533>.

44. Greenman Y, Cooper O, Yaish I et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 2016; 175(1): 63–72. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-16–0206>.

45. Samson SL, Ezzat S. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. Endocr Pract 2014; 20(6): 608–616. Dostupné z DOI: <http://dx.doi.org/10.4158/EP14148.RA>.